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Human peritoneal mesothelial cell prostaglandin synthesis: Induction
of cyclooxygenase mRNA by peritoneal macrophage-derived cytokines.
Increasing evidence suggests that the mesothelial cell contributes to the
control of inflammation in both the normal and inflamed peritoneal cavity.
The present study examines the regulation of prostaglandin production by
human peritoneal mesothelial cells (HPMC) following stimulation with
peritoneal macrophage-conditioned medium and the cytokines interleu-
kin-lp (IL-113) and tumor necrosis factor-a (TNF-a). IL-113 and TNF-a
stimulated significant release of prostaglandin above background levels in
a time and dose dependent manner. Stimulation of HPMC with IL-1/3
(500 pg/mI) or TNF-a (100 pg/mI) for 24 hours resulted in the release of
24.5 4.3 (N = 11) (z = 3.40, P < 0.001 vs. control) and 19.4 4.5(N = 10; z 3.29, P < 0.001 vs. control) pg 6-keto-PGF1/g cellular
protein, respectively. Pretreatment of HPMC with dexamethasone (10_6
to i0 M) inhibited both constitutive and cytokine stimulated prostag-
landin synthesis in a dose dependent manner. Both PM0-CM and
PM0-S.epiCM stimulated 6-keto-PGF1,, and PGE2 synthesis by HPMC in
a time and dose dependent manner (PM0-S.epiCM >> PM0-CM).
Co-incubation of HPMC with PM0-S.epiCM in the presence of anti-IL-1/3
and/or anti-TNF-a antibody, interleukin-1 receptor antagonist or soluble
TNF receptor (TNF p75) significantly reduced the capacity of these
supernatants to stimulate prostaglandin synthesis. Exposure of HPMC to
cytokines or PMØ-S.epiCM resulted in the time dependent increase in the
levels of both Cox-1 and Cox-2 mRNA as assessed by RT/PCR analysis
with the greatest increase being seen for Cox-2. These data demonstrate
specific stimulation of eicosanoid metabolism in HPMC by peritoneal
macrophage derived cytokines, indicating the possible importance of these
mediators in the activation of intraperitoneal prostaglandin synthesis.
HPMC prostaglandins might act as important pro/anti-inflammatory
mediators contributing to a cytokine network in the peritoneal cavity
during CAPD peritonitis.
It has been suggested that long-term exposure to non-physio-
logical peritoneal dialysis solutions adversely affects the structure
and function of the peritoneal membrane [1] and that the
destruction of the mesothelial layer might result in increased
peritoneal permeability and membrane damage leading to loss of
ultrafiltration capacity [21. Damage to the peritoneal membrane is
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further exacerbated by episodes of peritonitis which are accom-
panied by a significant increase in the loss of plasma proteins into
the dialysate [3].
The precise mechanisms which govern this change in peritoneal
permeability are poorly understood, but vasoactive arachidonic
acid metabolites appear to play a significant role in the control of
fluid movement [4]. Moreover, it has been postulated that the
permeability of the peritoneal membrane to plasma proteins
correlates with intraperitoneal prostaglandin levels which are
significantly elevated during the early stages of infection [5, 6].
In addition to their vasoactive action prostaglandins can also act
to control inflammation via their ability to inhibit cytokine release
from inflammatory cells [7, 8]. It is not known whether prostag-
landins function in this manner in the peritoneal cavity although
during peritonitis their increased levels may serve as a feedback
mechanism controlling the inflammatory process.
The source of intraperitoneal eicosanoids is not known, al-
though the mesothelial cell, the largest resident cell population,
must be considered as one of the major candidate cells for their
generation [6]. In this respect studies of arachidonic acid metab-
olism by isolated peritoneum and by cultured mesothelial cells
from other species have demonstrated that prostacyclin and PGE2
are the predominant eicosanoid species produced by this cell type
[9—12], and it has therefore been postulated that these cells may
be the main source of prostaglandins in serous tissues.
While the source of prostaglandins may be the endogenous cells
of the peritoneal cavity, the control of their synthesis is likely to
rest with pro-inflammatory cytokines secreted from invading
inflammatory phagocytes. During peritonitis both neutrophil and
peritoneal macrophage numbers are dramatically increased, and
recently, increased levels of cytokines in peritoneal dialysis fluid
during peritonitis have been demonstrated [13—151. In this context
it has been shown that peritoneal macrophages (PM0) isolated
from patients during episodes of infection are primed for en-
hanced IL-lp and TNF-a release [13—18], suggesting an increased
capacity to generate these potent inflammatory cytokines. Under
the same conditions, however, the synthesis of prostaglandins by
these cells was not up-regulated.
We have previously described the isolation and growth of
human peritoneal mesothelial cells (HPMC), and have more
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recently demonstrated that these cells may be important contrib-
utors to an intraperitoneal cytokine network controlling inflam-
mation via their secretion of interleukin-6 (IL-6) and interleukin-8
(IL-8) [19, 20]. The present study investigates HPMC arachidonic
acid metabolism following exposure to peritoneal macrophage
supernatants and recombinant cytokines (IL-113 and TNF-a). The
stimulatory activity of PMØ supernatants is further characterized
and indicates a potential role for secreted IL-i and TNF-a in the
activation of mesothelial cell arachidonic acid metabolism during
peritoneal infection. Our data indicate that HPMC prostaglandins
may be an important component of the cytokine network control-
ling inflammatory events in the peritoneal cavity.
Methods
All chemicals were obtained from the Sigma Chemical Com-
pany Ltd (Poole, Dorset, UK) unless otherwise stated. Recombi-
nant human IL-113 was a gift from Dr. D. Boraschi (Sciavo
Research Centre, Siena, Italy). Its specific activity was 2.5 x io
U/mg as assessed in the EL-4 16/CTLL bioassay. Human TNF-a
was from BASF AG (Ludwigshafen, Germany). Its specific activ-
ity was 8 x iO U/mg protein (as assessed in a 48-hr L929 bioassay
in the absence of actinomycin D). All cytokine preparations were
batched and stored at —70°C and freshly thawed for each
experiment. Endotoxin contamination of recombinant material
was <0.7 pg protein as assessed by the limulus amoebocyte
lysate assay (Kabi Vitrum, Stockholm, Sweden). Goat anti-human
IL-1f3 and goat anti-human IL-6 antisera were gifts from The
National Institute of Biological Standards and Control (NIBSC;
Potters Bar, Herts, UK) and monoclonal anti-TNF-a antibody
(mono Ab 195) was provided by BASF AG, Human recombinant
IL-ira and TNF p75 were gifts from Dr. Peter Scholz (Schering
AG, Berlin, Germany).
Isolation and culture of human peritoneal mesothelial cells
Human peritoneal mesothelial cells (HPMC) were obtained
from the omental tissue of consenting patients undergoing elec-
tive abdominal surgery. The cells were isolated and characterized
essentially as described previously [21]. The cells cultured were
identified as pure mesothelial cells by their uniform cobblestone
appearance at confluence, by the presence of surface microvilli, by
the lack of staining for factor VIII related antigen and the uniform
positive staining for cytokeratins 8 and 18. The presence of
contaminating macrophages was excluded following examination
of Fc receptor expression (using a red cell rosetting assay which
was negative in all mesothelial cell cultures examined). It has been
suggested that cells derived from digestion of omental tissue
might be microvascular endothelial cells. Recent evidence, how-
ever, suggests that these cells are in fact of mesothelial and not
endothelial origin [22—24]. In addition, we have previously dem-
onstrated that these cells do not secrete endothelin-1, a charac-
teristic of endothelial cells [20].
Cells were maintained in Hams F12 (Sera Lab/JRH Biosciences
Ltd, Crawley, UK) supplemented with penicillin (100 U/mI),
streptomycin (100 sg/ml), L-glutamine (2 mM) (Gibco BRL Life
Technologies Ltd, Uxbridge, UK), transferrin (5 sg/ml), insulin (5
jtg/ml), hydrocortisone (0.4 g/ml) (all from Sigma) and 10%
vol/vol fetal calf serum (FCS) (Sera Lab Ltd). HPMC cultures
were incubated at 37°C in a humidified 5% CO2 atmosphere.
Cells were passaged using tiypsin:EDTA:glucose solution
(0.125% wt/vol:0.01% wt/vol:0.1% wt/vol). All data presented are
from experiments performed with cells from the second passage
which had previously been growth arrested as described below
There was no difference in reactivity pattern of mesothelial cell
cultures irrespective of passage number. Cells were used from the
second passage and not later to maximize cell numbers but to
avoid using cultures containing senescent cells which appeared
from the third passage onwards [19].
Establishment of growth an'ested HPMC
HPMC were grown to confluence on type I collagen [25]
treated 250 ml flasks or in collagen treated multi-well plates
(Falcon, Becton Dickinson, Oxford, UK). The medium was then
removed and Hams F12 medium containing 0.1% vol/vol FCS
(Basal medium) was added to the cells for 48 hours prior to
stimulation. Previous experiments had demonstrated that at this
time point the cells were maintained in a viable [as assessed by the
lack of lactate dehydrogenase (LDH) release] but non-prolifera-
tive state. Under these conditions the cells could be maintained
for up to 96 hours without any significant loss of viability.
Peritoneal macrophage (PM0) conditioned medium
PMØ were harvested from infection free peritoneal dialysis
(PD) effluent of patients undergoing continuous ambulatory
peritoneal dialysis at Cardiff Royal Infirmary as previously de-
scribed [26]. The isolated cell population was resuspended in
Hams F12 medium containing 0.1% wt/vol bovine serum albumin
(BSA; ICN Biomedicals Ltd) to a cell density of 2 x 106/ml. One
milliliter of this suspension was plated onto 35 mm Petri dishes
(Nunclon; Gibco/BRL Life Technologies Ltd, Paisley, UK) and
incubated at 37°C in a CO2 incubator for 90 minutes. After this
period the non-adherent cells were removed by washing twice with
warm Hams F12 (0.1% FCS) medium. Greater than 95% of the
cells remaining adherent to the plates were PMØ as assessed
morphologically following differential cell staining (Neat stain;
Guest Medical Ltd, Sevenoaks, UK).
Conditioned medium was collected from adherent PMØ fol-
lowing a three hour incubation with Hams F12 (0.1% FCS) alone
(PM0-CM) or from PMØ stimulated with a strain of Staphylo-
ccocus epidermidis (S.epidermidis DM), isolated from the effluent
of a CAPD patient with peritonitis, as previously described
(PM0-S.epi-CM) [27].
Cytokine release measurements
Interleukin-1/3 (IL-113) and interleukin-la (IL-la) were mea-
sured in the supernatants of control and stimulated PMØ by
specific RIA as previously described [28, 29]. Tumor necrosis
factor a (TNF-a), interleukin-8 (IL-8) and interleukin-6 (IL-6)
were measured by sandwich ELISA as previously described [20,
30].
Induction of prostaglandin production by HPMC
HPMC monolayers were grown to confluency in collagen-
coated 24 well plates (Falcon, Beckton-Dickinson UK Ltd, Ox-
ford, UK), and growth arrested for 48 hours in Hams F12
containing 0.1% vol/vol FCS as previously described, washed four
times with basal medium, and then incubated at 37°C in the
presence or absence of the cytokine or conditioned medium to be
tested. At specific time intervals HPMC supernatants were re-
moved, centrifuged at 12,000 X g and then stored at —70°C until
assayed. At the end of the incubation period the cells were washed
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three times with PBS (pH 7.3) (Dulbecco; Oxoid Ltd, Basing-
stoke, UK) and the cellular protein solubilized with 0.1 N NaOH.
Total cellular protein was estimated in these supernatants using
the modified Bradford method [31]. Repeated cell counts re-
vealed that 1 jtg of cellular protein was equivalent to 3.76 0.56
X io cells (N = 20). All data for prostaglandin production are
expressed as pg/pg of cellular protein.
Incubation of HPMC with doses of recombinant cytokines,
PM0-CM or PM0-S.epiCM for up to 48 hours did not have any
significant effect on cell viability as assessed by LDH release (data
not shown) or on the levels of cellular protein per well as
compared to cells treated with medium alone [Control; 45.29
3.42 vs. IL-1 (500 pg/ml); 44.46 3.62 (N = 24), Control; 46.61
3.85 vs. TNF-a (1000 pg/mI); 47.47 3.38, (N = 24) and
Control; 39.29 4.14 vs. PM0-CM; 41.62 2.59, (N = 11) and
PM0-S.epiCM; 42.17 4.64, (N = 11), mean SEM (g/well)
respectively]. None of these differences was statistically signifi-
cant.
Prostaglandin radioimmunoassay
The prostaglandin content of the HPMC supernatants was
assessed directly by RIA using specific antibodies directed against
PGE2 and 6-keto-PGF1 ,. The characterization and cross reactiv-
ities of these antibodies have been previously described [32]. The
radioimmunoassays for the different eicosanoids had detection
limits (10% specific tracer displacement) of 20 pg for PGE2 and
10 pg for 6-keto-PGF1.
High performance liquid chromatography (HPLC)
HPMC were grown to confluency in collagen coated 250 ml
tissue culture flasks (Falcon) washed twice with PBS and prela-
belled for 24 hours at 37°C with 5 tCi/flask [5,6,8,9,11,12,14,15-
3H(N)]-arachidonic acid (NET-298, 94.5 Ci/mmol; NEN, DuPont
Ltd, Stevenage, UK) in Hams F12 medium containing 0.1%
vol/vol FCS. The cells were washed three times with CM and then
twice with PBS and stimulated for 24 hours at 37°C with IL-1/3
(500 pg/mI). [3H]-eicosanoids were extracted and purified by solid
phase extraction (Amprep Ethyl C2; Amersham International plc,
Aylesbury, UK) and separated by reverse phase HPLC (Anachem
Ltd, Luton, UK) on an Apex C18 (Jones Chromatography,
Cardiff, UK) column. The mobile phase consisted of 33% vol/vol
acetonitrile: 67% water (pH 3.7). The peaks of radioactivity
measured were compared to those of authentic [3H] standards
(NEN, Boston, Massachusetts, USA) run on the same day. The
retention times of the authentic standards were: 6-keto-PGF1 9
1, PGE2 22 1.5, and TXB2 15 2 (mean so, N = 3) mm.
RNA isolation, reverse transcription and PCR amplification
HPMC were grown to confluence in T25 flasks (Falcon, Beck-
ton-Dickinson, Oxford, UK), growth arrested as previously de-
scribed and stimulated with IL-1/3 (1000 pg/ml), TNF-a (1000
pg/ml), PMØ-S.epiCM or control medium for various defined
time periods up to 24 hours at 37°C. Total cellular RNA was
extracted from both control and cytokine treated HPMC follow-
ing lysis with 4 M guanidine isothiocyanate and centrifugation
through 5.7 M cesium chloride in 0.1 M EDTA [33]. Total RNA
was reverse transcribed into cDNA with M-MLV°' reverse tran-
scriptase (Gibco Life Technologies Ltd, Paisley, UK), using the
random hexamers method as previously described [20, 34]. Briefly,
the reaction mixture contained 1 1 random hexamers (100 jtM,
Table 1. Amplification primers
Sequence
Gene Primers Size reference
a-Actin Forward-GGAGCAATGAT-
ITITGATCTIT
Reverse-TCCTGAGGTACG-
GGTCCTFCC
204 bp [34]
Cox-1 Forward-GGCCTTGGGCC-
ATGGGGTAG
Reverse-AGCTGCT'CATC-
GCCCCAGGT
318 bp [35]
Cox-2 Forward-AACCCACTC-
CAAACACAG
Reverse-CTGGCCCTCGC-
TFATGATCT
411 bp [36]
Pharmacia Biosystems Ltd, Milton Keynes, UK), 5 il NTP's (2.5
mM, Gibco/BRL Life Technologies, Ltd), 2 d lox PCR buffer
(100 mtvi Tris/HC1, 500 mrvi KCI, 15 mti MgC12 and 0.01% wt/vol
gelatin), 2 d DTT (0.1 M, Gibco/BRL Life Technologies, Ltd),
1 d RNAase inhibitor (Promega, Southampton, UK), 1 d
M-MLV Superscript reverse transcriptase (200 Units, Gibco/
BRL Life Technologies, Ltd), and 1 g of total RNA.
PCR amplification was performed in a total volume of 50 d (2
d of reverse transcription product and 48 d of master mix (36.25
.d H2O, 1.25 .d 5'-primer (20 j.tM), 1.25 Ll 3'-primer (20 jiM), 4 jil
NTP's, 5 jil lOx PCR buffer and 0.25 jil Taq polymerase (2.5 U,
Amplitaq©, ILS Ltd, London, UK) using a Perkin Elmer Ther-
mocycler 480 (Applied Biosystems Ltd, Warrington, UK). The
PCR protocol was as follows:- 1st cycle 94°C for 3 mm, 55°C for
1 mm, 72°C for 1 mm; 2 to 24th cycles 94°C for 40 sec, 55°C for 1
mm, 72°C for 1 mm. The final cycle was 94°C for 1 mm and 60°C
for 10 mm. PCR was performed for 25 cycles with a-actin and 24
to 30 cycles for Cox-1/Cox-2. One-tenth of the PCR reaction from
both test (Cox-1 and 2) and control (a-actin) products was mixed
and separated by flat bed electrophoresis in 3% wt/vol NuSieve
GTG agarose gels (Flowgen Instruments Ltd, Sittingboume, UK),
stained with ethidium bromide (Sigma) and photographed. The
negatives were scanned using a densitometer (Model GS670 video
densitometer, Bio-Rad Laboratories Ltd, Hemel Hempstead,
UK) and the density of the bands compared to those of the
housekeeping gene. Data are expressed as the mean (±sEM) fold
increase in the Cox/cv-actin ratio compared to the ratio of mRNA
expression in unstimulated HPMC performed under identical
PCR conditions,
The oligonucleotide primers for Cox-1 were complimentary to
bases 658-687 in the Cox-1 cDNA in the case of the forward
primer and bases 966-985 in the Cox-1 cDNA in the case of the
reverse primer. The oligonucleotide primers for Cox-2 were
complimentary to bases 300-3 19 in the Cox-2 eDNA in the case of
the forward primer and bases 691-711 in the Cox-2 eDNA in the
case of the reverse primer. These oligonucleotides amplified a 318
bp fragment in the Cox-1 sequence and a 411 bp fragment in the
Cox-2 sequence.
The sequences of the amplification are in Table 1.
Inhibition experiments
In a separate series of experiments, HPMC were exposed to
PM0-S.epiCM in the presence or absence of increasing concen-
trations of (a) polyclonal goat anti-human IL-1/3, (b) monoclonal
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anti-human TNF-a, (c) IL-ira (0.1 to 100 ng/ml), or (d) TNF p75
(0.1 to 100 ng/ml) throughout the period of stimulation (24
hours). Supernatants from these experiments were assayed for
6-keto-PGF1 as previously described and the data corrected for
cellular protein content.
Dexamethasone inhibition
Growth arrested HPMC were pre-exposed to increasing con-
centrations of Dexamethasone (10 to 10—6 Sigma) for three
hours prior to stimulation with IL-113 (1000 pg/ml) TNF-a (1000
pg/mi) or control medium for 24 hours. Supernatants from these
experiments were collected and assayed for 6-keto-PGF1 as
previously described.
Statistical analysis
Statistical analyses were performed by using the Wilcoxon
signed rank test for paired non-parametric data (Statview 512;
Apple Macintosh, Cupertino, California, USA). All data are
presented as mean SEM.
Results
HPMC prostaglandin production
Unstimulated growth-arrested HPMC maintained in medium
containing 0.1% vol/vol FCS released both 6-keto-PGF1 and
PGE2 constitutively. This release became significant above time
zero after three to four hours, reaching a plateau between 24 and
48 hours (data not shown). After 24 hours the levels of 6-keto-
PGF and PGE2 were 11.2 3.81 and 3.38 1.13 (N = 21)
pg/pg cell protein, respectively. TXB2 levels in unstimulated
HPMC remained undetectable by RIA throughout the whole time
course studied.
Induction of HPMC prostaglandin production by IL-I f3 and
TNF-o
Both IL-1/3 and TNF-a stimulated the release of 6-keto-PGF1
and PGE2 from growth arrested HPMC in a dose dependent
manner (Fig. 1 A and B). For PGE2 this release was significantly
above control at all doses of IL-1f3 >0.5 pg/mi and for doses of
TNF-a >1 pg/mi. 6-Keto-PGF1 levels were significantly above
control for doses of IL-1/3 >5 pg/ml and for doses of TNF-a >1
pg/ml. Following stimulation of HPMC with IL-1/3 (500 pg/mI) or
TNF-a (100 pg/mI) for 24 hours, 6-keto-PGF1 production was
24.5 4.3 (N = 11; z = 3.40, P < 0.001 vs. control) and 19.4
4.5 (N = 10; z = 3.29, P < 0.001 vs. control) pg/jig cellular
protein, respectively. The 24 hour release of PGE2 increased over
the whole dose range, for both cytokines, reaching 13.64 1.73 (N
= 11; z = 2.803, P < 0.01) and 9.83 2.36 (N = 10; z = 3.059,
P < 0.00 1) pg/.ig cellular protein following stimulation with IL-1f3
(5000 pg/mI) and TNF-s (1000 pg/mI), respectively. Irrespective
of the donor HPMC, dose or type of stimulation the release of
6-keto-PGF was always greater than PGE2 release.
The response to IL-113 and TNF-a was also time dependent; in
each case the stimulated release of 6-keto-PGF1 and PGE2 only
became significant above background after a lag phase of between
three and six hours (Fig. 2 A and B). At the doses selected the
release of 6-keto-PGF in response to IL-1p reached a plateau by
24 hours, while the release in response to TNF-a continued to rise
over the whole time course studied. The release of PGE2 in-
creased over the whole time course in response to both cytokines.
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Fig. 1. A. Dose effect of IL -1 f3 on the 24 hour generation of 6-keto-PGF1
() and PGE2 (LI) by HPMC. The data presented is the mean (±sEM)
prostagiandin release from 11 separate experiments with HPMC prepared
from separate omentai specimens. B. Dose effect of TNF-a on the 24 hour
generation of 6-keto PGF1 and PGE2 by HPMC. The data presented are
the mean (±sEM) prostaglandin release from 10 separate experiments
with HPMC prepared from separate omental specimens. * Represents a
statistically significant difference compared to the control unstimulated
prostagiandin release value.
The stimulatory effects of both cytokines were specific since
pre-incubation of either cytokine with excess of either polyclonal
anti-IL-1f3 (in the case of IL-1/3) or monoclonal anti-TNF-a (in
the case of TNF-a) antibody reduced the ability of these cytokines
to stimulate HPMC prostaglandin production over the whole dose
range tested. At an IL-1(3 concentration of 500 pg/ml, 6-keto-
PGFI and PGE2 release was reduced by means of 88.73 and
82.73% (N = 3), respectively, while the prostaglandin response to
TNF-c (1000 pg/mi) was reduced by means of 97.5 and 92.3% (N
= 3), respectively.
HPLC analysis of growth anested HPMC
Reverse phase HPLC analysis of purified and extracted HPMC
supernatants derived from cells pre-labeled with [3H1-arachidonic
acid and stimulated with IL-1f3 (500 pgJml) demonstrated that the
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Cytokine PM0-CM PM0-S.epi-CM
IL-1/ 1600 1273 2359 768
IL-la 55 7.25 82.5 12.37
TNF-a 451 117 720 252
IL-6 71.8 12.36 161 55.26a
IL-8 948 179 1199 257
PGE2 above the levels generated by each cytokine alone. The
level of release, however, was not significantly different from the
additive values of the two cytokines when each was added singly to
________________________________________
HPMC. Peak stimulation of 6-keto-PGF1 and PGE2 was ob-I I I I I I I I tained at the highest combination of cytokine concentrations0 6 12 18 24 30 36 42 48
tested (IL-113, 5000 pg/mi + TNF-a, 1000 pg/mI) when the 24 hour
Time, hours releaseswere 24.5 7.7 and 17.18 10.6 pg/jig cell protein (N =
5) respectively.
PMØ-CM and PM0-S.epi CM cytokine release and prostaglandin
Time, hours
Fig. 2. A. Time dependent generation of ó-keto-PGF1, from HPMC
stimulated with IL-i $3 (500 pg/mI, —0—) or TNF-a (500 pg/mI, --0--). The
data presented are the mean (±sEM) prostaglandin release from 5
separate experiments with HPMC prepared from separate omental spec-
imens. B. Time dependent generation of PGE2 from HPMC stimulated
with IL-1$3 (500 pg/mI) or TNF-a (500 pg/mI). The data presented are the
mean (±sEM) prostaglandin release from 5 separate experiments with
HPMC prepared from separate omental specimens. * Represents a statis-
tically significant difference compared to the control unstimulated pros-
taglandin release value.
major products synthesized by these cells, 6-keto-PGF1, and
PGE2, had retention times of 9 1 and 22 1 mm, respectively,
corresponding with those of authentic standards run on the same
day.
Combined cytokine stimulation of HPMC
The simultaneous addition of different doses of IL-113 and
TNF-a to HPMC resulted in the generation of 6-keto-PGF1a and
.synthesis
In order to assess the role of macrophage products in the
stimulation of HPMC prostaglandin synthesis, PMØ supernatants
were assessed for cytokmne and prostaglandin content. PMØ
incubated for three hours in control medium (Hams F12 contain-
ing 0.1% FCS) (PM0-CM) released significant levels of IL-1/3,
IL-la, TNF-a and IL-6 as assessed by RIA or ELISA. Following
stimulation with S.epidermidis for three hours the levels of IL-1f3,
TNF-a, IL-8 and IL-6, but not IL-la, in the supernatants (PM0-
S.epiCM) were significantly increased (Table 2). The levels of
6-keto-PGF1,, and PGE2 in PM0-CM (264.3 63.4 and 110.0
23.5 pg/mi, N = 9, respectively) were not significantly different
from prostaglandin levels following stimulation with S.epiderinidis
(289.9 85.3 and 158.7 48.6 pg/ml for 6-keto-PGF1 and PGE2,N = 9, respectively).
PMØ conditioned medium induces HPMC prostaglandin
production
The addition of 3-hour control or stimulated conditioned
medium from peritoneal macrophages (PM0-CM and PM0-
S. epiCM) to HPMC triggered significant release of 6-keto-PGF1,
and PGE2 in a time dependent manner. At equivalent dilutions
(and after subtraction of PMØ prostaglandin release) the level of
prostaglandin stimulation induced by PM0-S.epiCM was always
significantly higher than that induced by the equivalent dose of
PM0-CM across the whole dilution range tested (Fig. 3 A and B).
At equal dilutions (1:10) the levels of prostaglandin generated
were: 6-keto-PGF1,, 42.22 11.48 (N = 6) and 81.33 14.28 (N
= 6; z = 2.66, P < 0.01) and PGE2 15.28 5.43 (N = 6; z = 2.31,
P < 0.01) and 32.88 11.41 (N = 5; z = 2.38, P < 0.01) by
PM0-CM and PM0-S.epiCM, respectively. Maximal stimulation
of HPMC PGE2 production by PM0-CM and PM0-S.epiCM
occurred at the highest dilution tested (1:2) while maximal
stimulation of HPMC 6-keto-PGF1,, production by PM0-CM and
PM0-S.epiCM occurred at dilutions between 1:5 and 1:10. The
three-hour cell free culture supernatants from S.epidennidis DM
alone did not stimulate HPMC prostaglandin release under the
experimental conditions tested (data not shown).
*
*
A Table 2. Release of cytokines following a 3 hour incubation in the
presence or absence of S. epidermidis DM
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Control 2 5 10 20
Fig. 3. A. Dose effect of increasing dilutions of PMØ-CM on the capacity of
HPMC to release 6-keto-PGF1a () and POE2 (0). Data presented as
pg/gg cell protein (after subtraction of the prostaglandin levels present in
PM0-CM) are the mean (±snM) of 6 separate experiments with HPMC
prepared from separate omental specimens. 13. Dose effect of increasing
dilutions of PM0-S.epicM on the capacity of HPMC to release 6-keto-
POFia and POE2. Data presented as pg/gg cell protein (after subtraction
of the prostaglandin levels present in PM0-S.epiCM) are the mean
(±5EM) of 6 separate experiments with HPMC prepared from separate
omental specimens. *Represents a statistically significant difference com-
pared to the unstimulated release of prostaglandins by HPMC.
PCR analysis of HPMC Cox mR/VA expression
HPMC mRNA isolated from control and cytokine stimulated
cells was reverse transcribed and subjected to PCR amplification.
These experiments demonstrated the generation of specific single
band transcripts of 318 and 411 base pairs for Cox-1 and Cox-2,
respectively, in all HPMC cell lines examined. Treatment of
HPMC with IL-113, TNF-a or PM0-S.epiCM resulted in a time
dependent increase in the expression of Cox-2 mRNA and a much
smaller but consistent increase in Cox-1 expression in all experi-
ments (N = 3, HPMC preparations; Fig. 4 A, B and C). The levels
of Cox-2 mRNA were increased maximally by 5.47-, 5.46- and
21.48-fold (Coxlcw-aetin ratio) above control in response to IL-lp,
TNF-a or PM0-S.epiCM, respectively. The induction of Cox-1
was much less dramatic with maximal increases of 2.02-, 1.6- and
1.94-fold above unstimulated controls (N = 3).
Inhibition studies
Antibody inhibition. Coincubation of HPMC with PM0-S.epiCM
in the presence of excess of anti-IL-1/3 antiserum or anti-TNF-a
monoclonal antibody resulted in a reduction in the capacity of these
supernatants to stimulate the release of both 6-keto-P0F and
POE2. Under optimal conditions (1:10 dilution) POE2 stimulating
capacity was reduced by 48.7 10.3% and 29.4 7.5% (mean
SENt, N = 5; z = 1.96, P < 0.05 for both) with anti-IL-1j3 and
anti-TNF-a antibodies, respectively (Fig. 5). Inhibition of 6-keto-
POFia release under the same conditions (1:10 dilution) reached
51.3 9% and 29 15% (N = 6; z = 1.96, P C 0.05 for both) with
anti-IL-1/3 and anti-TNF-a antibodies, respectively (Fig. 5). Coineu-
bation of HPMC with PM0-S.epiCM in the presence of excess
anti-IL-6 antibody did not result in any significant inhibition of either
6-keto-PGF1 or POE2 production (data not shown).
Inter/eu/tin-i receptor antagonist/TNFp75 soluble receptor. Coin-
eubation of HPMC with PM0-S.epiCM in the presence of increas-
ing concentrations of IL-ira or TNF p75 resulted in a reduction in
the capacity of these supernatants to stimulate the release of
6-keto-PGF. At the highest concentration of inhibitors added
(100 ng/ml) HPMC synthesis of 6-keto-PGFia was reduced from
53.13 19.4 (mean SEM, N = 5, pgtrg cell protein) in control
cells to 22.92 10.08 and 15.44 4.12 (pg/gg cell protein) in cells
exposed to TNF p75 and IL-ira, respectively (z = 1.96, P C 0.05
for both; Fig. 6).
Dexamethasone inhibition
Pre-exposure of HPMC to dexamethasone for three hours at
37°C resulted in a dose dependent inhibition of both constitutive
and cytokine stimulated 6-keto-POFia release. Maximal inhibi-
tion was evident at the highest dose tested (10—6 M Dexametha-
sone) when 6-keto-PGF release was reduced by means of 52.5,
64 and 63.8% for IL-1/3, TNF-a and constitutive release respec-
tively (N = 3, seperate experiments; Fig. 7).
Discussion
The present study examines prostaglandin synthesis by cultured
human peritoneal mesothelial cells following exposure to inflam-
matory cytokines and the conditioned medium from unstimulated
and stimulated peritoneal macrophages. HPMC released prostag-
landins in the absence of exogenous stimulation in a time depen-
dent manner. Previous studies have established that both IL-1$
and TNF-a are potent indueers of all prostaglandin species in
several cell types [37, 38]. In common with these findings both
eytokines induced a dose and time dependent release of prosta-
cyclin (measured as its stable breakdown product 6-keto POFI)
and POE2 from HPMC. HPLC and RIA analysis of this release
demonstrated that prostacyclin was the predominant arachidonic
acid metabolite, a finding which is in keeping with previous studies
with cultured mesothelial cells from other species [101.
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cytokine induced increases in prostaglandin synthesis in various synthase (cyclooxygcnase) enzyme, which in most cases is pro-
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this also appears to be the case since both cytokines and PMØ
conditioned media increased the expression of cyclooxygenase
mRNA. It is now known that two forms of cyclooxygenase exist in
various species (Cox-1 and Cox-2) [36, 43]. The expression of both
forms of cyclooxygenase appears to play an important role in the
generation of prostanoids by many cell types, although it remains
unclear to what extent each contributes to the final amount of
product generated. Recent data suggest that following stimulation
with various agonists, including interleukin-1, PMA, or LPS, that
Cox-2 mRNA and protein are preferentially induced while the
levels of Cox-1 mRNA and protein remain largely unchanged or
are marginally increased [42, 44—46]. These observations suggest
that sustained increases in prostaglandin release may be primarily
related to the induction of the Cox-2 gene. In the present study
the levels of Cox-2 mRNA were increased manyfold following
stimulation, but there was also a smaller but consistent increase in
LL000
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Fig. 7. Inhibition of HPMC 6-keto-PGF1 release by increasing concentra-
tions of Dexamethasone. Data presented are the mean 6-keto-PGF1
release from duplicate wells from a single representative experiment of
three (E control; IL-1j3; TNF-a) performed with separate HPMC
preparations. Dexamethasone inhibition of IL-113 (—s—), TNF-a (—0—)
and constitutive (—E—) 6-keto-PGF1 release.
the level of Cox-1 mRNA. These data suggest that the control of
prostaglandin synthesis in HPMC is related to an increase in the
specific mRNA for both forms of cyclooxygenase. The magnitude
of the increase in Cox-2 mRNA, however, would suggest that this
form of the enzyme may be the most important, in terms of
eicosanoid synthesis, in HPMC. In this respect the observation
that both constitutive and cytokine stimulated HPMC prostag-
landin synthesis was dose dependently inhibited by pre-treatment
with dexamethasone suggests an important role for Cox-2 in
prostaglandin generation in these cells. Glucocorticoids appear to
selectively inhibit the accumulation of Cox-2 mRNA in fibroblasts
[47, 48].
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The conditioned medium from control or S.epidermidis stimu-
lated PMØ also induced prostaglandin release from HPMC in a
time and dose dependent manner. Inhibition studies, utilizing
specific anti-cytokine antibodies, IL-ira and TNF soluble receptor
clearly demonstrated that the stimulatory capacity of PM0-
S.epiCM was primarily related to their IL-13 and TNF-cv content.
These data confirm the recent findings of Betjes et al [49], who
demonstrated that antibodies to IL-i and/or TNF-a reduced the
stimulation of HPMC IL-8 by PMØ conditioned media. The
stimulation of prostaglandin synthesis by PMØ supernatants also
appeared to be related to an increase in HPMC cyclooxygenase
mRNA expression, since both Cox-1 and to a much greater extent
Cox-2 mRNA were increased following stimulation.
The passage of proteins across the peritoneal membrane during
bacterial peritonitis is related directly to the prostaglandin content
of dialysis fluid, which suggests that local production of vasodila-
toly substances controls the permeability of this membrane [5, 6],
These studies have proposed the mesothelium as the main source
of these effector molecules. The present study confirms that this
may indeed be the case and further suggests that it is possible
during peritonitis for locally produced cytokines, derived from
activated macrophages and mesothelial cells, to contribute indi-
rectly to peritoneal hyperemia.
The present data provide additional evidence that the mesothe-
hal cell contributes directly to the control of intraperitoneal
inflammatory processes and further demonstrates the possibility
of direct interaction between peritoneal macrophages and the
mesothelium. Increased intraperitoneal secretion of prostag-
landin may serve as a negative feedback loop inhibiting inflam-
mation, via down regulation of macrophage cytokine release [7, 8,
50,51], and might thus represent an important control mechanism
contributing to the intraperitoneal cytokine network [52] by acting
to control the extent of peritoneal inflammation in the clinical
situation of acute peritonitis.
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